Shandong Xinhua Pharmaceutical Co., Ltd. (00719) announced interim results, net profit of about 149 million yuan, a year-on-year decrease of 33.35%

According to the Zhitong Finance App, Shandong Xinhua Pharmaceutical Co., Ltd. (00719) announced its 2026 interim results, with operating income of about 4.358 billion yuan, a year-on-year decrease of 6.06%; net profit attributable to shareholders of listed companies was about 149 million yuan, a year-on-year decrease of 33.35%; and basic earnings per share were 0.21 yuan.

According to the announcement, the main reason for the decline in net profit was intense competition in the international and domestic markets during the reporting period. In order to consolidate and increase the market share of products, the prices of some products fell.

Twelve new products, including valsartan capsules and entacapone tablets, were launched in the first half of the year. The new formulation achieved sales revenue of RMB 182 million, an increase of 92.58% over the previous year. Sales of new API products in the domestic market have increased exponentially. High-purity fish oil EPA has achieved key breakthroughs in high-end international markets such as the US and Canada. The main plant of the high-end API Industrial Innovation Center project has been completed, equipment is being installed, and various oral liquid products have been successfully commercialized.